ABUS
Price
$3.19
Change
+$0.13 (+4.25%)
Updated
Mar 12, 04:59 PM (EDT)
Capitalization
578.9M
50 days until earnings call
AGEN
Price
$1.86
Change
-$0.18 (-8.78%)
Updated
Mar 12, 04:59 PM (EDT)
Capitalization
44.04M
Ad is loading...

ABUS vs AGEN

Header iconABUS vs AGEN Comparison
Open Charts ABUS vs AGENBanner chart's image
Arbutus Biopharma
Price$3.19
Change+$0.13 (+4.25%)
Volume$35.25K
Capitalization578.9M
Agenus
Price$1.86
Change-$0.18 (-8.78%)
Volume$5.6K
Capitalization44.04M
ABUS vs AGEN Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. AGEN commentary
Mar 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a StrongBuy and AGEN is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 13, 2025
Stock price -- (ABUS: $3.06 vs. AGEN: $2.05)
Brand notoriety: ABUS and AGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 93% vs. AGEN: 189%
Market capitalization -- ABUS: $578.9M vs. AGEN: $44.04M
ABUS [@Biotechnology] is valued at $578.9M. AGEN’s [@Biotechnology] market capitalization is $44.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileAGEN’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • AGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, ABUS is a better buy in the long-term than AGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 6 TA indicator(s) are bullish while AGEN’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 6 bullish, 4 bearish.
  • AGEN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than AGEN.

Price Growth

ABUS (@Biotechnology) experienced а -9.88% price change this week, while AGEN (@Biotechnology) price change was -20.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.72%. For the same industry, the average monthly price growth was -6.30%, and the average quarterly price growth was -7.80%.

Reported Earning Dates

ABUS is expected to report earnings on May 01, 2025.

AGEN is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (-0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABUS($579M) has a higher market cap than AGEN($44M). ABUS YTD gains are higher at: -6.575 vs. AGEN (-25.182). ABUS (-75.14M) and AGEN (-77.64M) have comparable annual earnings (EBITDA) . ABUS has more cash in the bank: 128M vs. AGEN (44.8M). ABUS has less debt than AGEN: ABUS (1.45M) vs AGEN (78.4M). AGEN has higher revenues than ABUS: AGEN (160M) vs ABUS (6.74M).
ABUSAGENABUS / AGEN
Capitalization579M44M1,316%
EBITDA-75.14M-77.64M97%
Gain YTD-6.575-25.18226%
P/E RatioN/A0.46-
Revenue6.74M160M4%
Total Cash128M44.8M286%
Total Debt1.45M78.4M2%
FUNDAMENTALS RATINGS
ABUS vs AGEN: Fundamental Ratings
ABUS
AGEN
OUTLOOK RATING
1..100
6452
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
6396
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (65) in the Biotechnology industry is in the same range as AGEN (97). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

ABUS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AGEN (100). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

ABUS's SMR Rating (95) in the Biotechnology industry is in the same range as AGEN (100). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

ABUS's Price Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for AGEN (96). This means that ABUS’s stock grew somewhat faster than AGEN’s over the last 12 months.

AGEN's P/E Growth Rating (94) in the Biotechnology industry is in the same range as ABUS (100). This means that AGEN’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSAGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 21 days ago
79%
Bullish Trend 23 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NOEMX11.53N/A
N/A
Northern Emerging Markets Equity Index
LMPIX33.92N/A
N/A
ClearBridge Appreciation FI
SCSDX16.94N/A
N/A
Allspring Common Stock Admin
SKSIX27.81N/A
N/A
AMG GW&K Small Cap Value I
PGKAX22.85N/A
N/A
PGIM Jennison Technology A